Abstract
Depression is a common co-morbidity in patients with cardiovascular diseases such as chronic coronary artery disease, acute coronary syndromes, post by-pass surgery and chronic heart failure. There is a significant body of evidence suggesting that the presence of depression is independently associated with a decline in health status and an increase in the risk of hospitalization and death for patients with coronary artery disease or congestive heart failure. Novel treatment modalities such as selective serotonin re-uptake inhibitors (SSRIs) may improve depressive symptoms and prognosis of post-myocardial infarction and heart failure patients interacting with the common pathophysiologic mechanisms of depression and cardiovascular disease. This review summarizes current experimental and clinical evidence regarding the pleiotropic effects of SSRIs on platelet functions, immune and neurohormonal activation, and cardiac rhythm disturbances in patients with cardiovascular disease. These bio-modulatory properties of SSRIs may be translated into improvement of patient clinical outcomes beyond their anti-depressant action.
Keywords: SSRIs, depression, cardiovascular disease, platelets, cytokines
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: Selective Serotonin Re-Uptake Inhibitors for the Treatment of Depression in Coronary Artery Disease and Chronic Heart Failure: Evidence for Pleiotropic Effects
Volume: 4 Issue: 4
Author(s): Ioannis Paraskevaidis, John T. Parissis, Katerina Fountoulaki, Gerasimos Filippatos and Dimitrios Kremastinos
Affiliation:
Keywords: SSRIs, depression, cardiovascular disease, platelets, cytokines
Abstract: Depression is a common co-morbidity in patients with cardiovascular diseases such as chronic coronary artery disease, acute coronary syndromes, post by-pass surgery and chronic heart failure. There is a significant body of evidence suggesting that the presence of depression is independently associated with a decline in health status and an increase in the risk of hospitalization and death for patients with coronary artery disease or congestive heart failure. Novel treatment modalities such as selective serotonin re-uptake inhibitors (SSRIs) may improve depressive symptoms and prognosis of post-myocardial infarction and heart failure patients interacting with the common pathophysiologic mechanisms of depression and cardiovascular disease. This review summarizes current experimental and clinical evidence regarding the pleiotropic effects of SSRIs on platelet functions, immune and neurohormonal activation, and cardiac rhythm disturbances in patients with cardiovascular disease. These bio-modulatory properties of SSRIs may be translated into improvement of patient clinical outcomes beyond their anti-depressant action.
Export Options
About this article
Cite this article as:
Paraskevaidis Ioannis, Parissis T. John, Fountoulaki Katerina, Filippatos Gerasimos and Kremastinos Dimitrios, Selective Serotonin Re-Uptake Inhibitors for the Treatment of Depression in Coronary Artery Disease and Chronic Heart Failure: Evidence for Pleiotropic Effects, Cardiovascular & Hematological Agents in Medicinal Chemistry 2006; 4 (4) . https://dx.doi.org/10.2174/187152506784111454
DOI https://dx.doi.org/10.2174/187152506784111454 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Urine IL-18 is a Biomarker of Early Acute Kidney Injury (AKI)
Recent Patents on Biomarkers Diagnostic Cardiac Catheterization in the Pediatric Population
Current Cardiology Reviews Gender Differences in Cancer-associated Venous Thromboembolism
Current Medicinal Chemistry Iontophoresis: Drug Delivery System by Applying an Electrical Potential Across the Skin
Drug Delivery Letters Cardiovascular disease management through restrained inflammatory responses
Current Pharmaceutical Design The Boundary between Hypochondriasis, Personality Dysfunction, and Trauma
Current Psychiatry Reviews Phosphatidylinositol 3-Kinase Isoforms as Novel Drug Targets
Current Drug Targets GDF11 Attenuated ANG II-Induced Hypertrophic Cardiomyopathy and Expression of ANP, BNP and Beta-MHC Through Down- Regulating CCL11 in Mice
Current Molecular Medicine Novel Therapeutic Strategy in the Management of COPD: A Systems Medicine Approach
Current Medicinal Chemistry The Role of Immunosuppressive Medications in the Pathogenesis of Hypertension and Efficacy and Safety of Antihypertensive Agents in Kidney Transplant Recipients
Current Medicinal Chemistry Antiproliferative Strategies for the Treatment of Vascular Proliferative Disease
Current Vascular Pharmacology Remediation of Cellular Hypoxic Damage by Pharmacological Agents
Current Pharmaceutical Design Improvement in Hypertension Management with Pharmacological and Non- Pharmacological Approaches: Current Perspectives
Current Pharmaceutical Design CPR Education
Current Pediatric Reviews Molecule of the Month
Current Topics in Medicinal Chemistry Milk Fat Globule Epidermal Growth Factor VIII Signaling in Arterial Wall Remodeling
Current Vascular Pharmacology Prevention and Treatment of Venous Thromboembolism and Pulmonary Embolism: The Role of Novel Oral Anticoagulants
Current Clinical Pharmacology Update in Pharmacological Management of Coronary No-Reflow Phenomenon
Cardiovascular & Hematological Agents in Medicinal Chemistry Sirolimus and its Analogs and its Effects on Vascular Diseases
Current Pharmaceutical Design Chromogranin A in Tumors: More Than a Marker for Diagnosis and Prognosis
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents